ranQ
ranQ
ranQ
DirectoryIndustriesPlacesKnowledgeComparisonsSoon
Sign inCheck visibility
ranQHSG Startup LabelRecognised by the
HSG Startup Label

The leading AI company directory, built to boost AI visibility.

DEENFRIT
Product
  • Pricing
  • Directory
  • Industries
  • Trust Score
Company
  • About
  • Contact
  • Legal
© 2026 cohaga AG · All Rights Reserved · St. Gallen, Switzerland · Imprint745,629 companies indexed · Last updated: today
DirectoryBusiness & Technical ServicesResearch & DevelopmentBaselBioVersys AG
BioVersys AG Logo
Verified· 3 sourcesTrust Score
Summary

About the company

The core activity of Bioversys AG is the development and manufacture of pharmaceuticals, particularly in the field of antibiotic research and the development of therapeutics for various diseases. The company is engaged in the research and development of small molecules, peptides and therapeutic polymers and has experts in the fields of medicinal chemistry, CMC (Chemistry, Manufacturing, Control) and biotechnology on its team.

AI-generated
Offering

Products & services

Industry:Research & DevelopmentPharmaceutical Industry
LeadhubOutbound Leads by COHAGA

Looking for direct email addresses and phone numbers?

Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.

Discover Leadhub
4.1/5

BioVersys AG

✓ Offered6
Drug research and development against antimicrobial resistance
Development of novel antibiotics with new mechanisms of action against antibiotic-resistant pathogens, in particular for severe hospital infections and other priority pathogens.
Drug research and development against tuberculosis
Development of a new anti-TB drug substance with a unique mechanism of action to potentiate ethionamide, including clinical testing in MDR-TB and TB meningitis.
Research and development of anti-virulence agents
Development of a first-in-class anti-virulence candidate against Staphylococcus aureus, including MRSA, for skin infections, pneumonia and atopic dermatitis.
Research and development against non-tuberculous mycobacterial infections
Development of a pipeline of compounds against NTM infections based on the company's proprietary ansamycin platform and the bacterial RNA polymerase target.
Drug discovery for ESKAPE pathogens
Development of small-molecule programs against important ESKAPE pathogens and other priority bacterial pathogens.
Collaboration and licensing projects in anti-infectives development
Out- and in-licensing, co-development, and partnerships with academic, funding and industry partners to further advance R&D programs.
Trust & reputation

ranQ Trust Score of BioVersys AG: 4.1 out of 5.0

Trust Score4.1/ 5.0

High

x

Data basis 58% · As of October 2026

Without public customer reviews the score stays capped.

BioVersys AG has no value in the Reputation area of the ranQ Trust Score because no data is available. The area carries 42% of the weighting and drops out of the calculation for this profile; it does not lower the score, only the reported data basis.
x
CriterionValueWeight
  • Review quality: No data point — the criterion is taken out of the weighting and does not lower the score.—24%
  • Review volume: No data point — the criterion is taken out of the weighting and does not lower the score.—10%
  • Review recency: No data point — the criterion is taken out of the weighting and does not lower the score.—8%
BioVersys AG scores 92.3 out of 100 points in the Substance area of the ranQ Trust Score. This area carries 28% of the weighting.
x
CriterionValueWeight
  • Establishment: Years since founding or brand launch, logarithmic. The maximum is reached at 15 years.100.012%
  • Company size: The headcount band, researched by ranQ or stated by the company. It is scored in steps rather than by head count, because the data only provides bands.82.07%
BioVersys AG scores 85.0 out of 100 points in the Identity area of the ranQ Trust Score. This area carries 22% of the weighting.
x
CriterionValueWeight
  • Verification: Official register entry (commercial register with UID or professional-body record, 55 points), confirmed domain (20 points) and confirmed ranQ profile (up to 25 points, depending on completeness).85.022%
BioVersys AG scores 60.0 out of 100 points in the Visibility area of the ranQ Trust Score. This area carries 8% of the weighting.
x
CriterionValueWeight
  • Website authority: Ahrefs' Domain Rating measures, on a scale of 0 to 100, how strongly a website is linked from other websites. For Swiss SMEs the range up to 40 is typical; the maximum is reached at 35.100.04%
  • Media authority: Quality and number of editorial mentions, weighted by the importance of the source, plus the recency of the latest high-quality mention.20.04%
Qualifications+0.00

BioVersys AG reaches a ranQ Trust Score of 4.1 out of 5.0 — rated «High». No public customer reviews are available for this provider; the rating is based on the remaining criteria. The data basis is 58%, so the score is backed by part of the criteria. As of October 2026.

The Trust Score cannot be bought and is calculated from publicly verifiable data.

Press

Media

November 10, 2025Media
Wellcome awards CHF 14 million for BioVersys’ BV100 Phase 2b study
startupticker.ch

Knowledge

No knowledge articles yet

Once BioVersys AG has claimed this profile, we'll publish editorial articles and case studies here together.

Get started
Comparisons

BioVersys AG in comparison

Soon

Industry comparisons are coming soon

We're preparing industry comparisons that rank BioVersys AG by reviews, experience and specialisations.

Is this your company?

Claim the company profile of BioVersys AG to make its contact details visible. With a plan we additionally create and publish industry comparisons, articles and much more.

Secure profile

Location

Hochbergerstrasse 60C
4057 Basel

At a glance

Legal form
Corporation
UID
CHE-114.512.761
Founded
2008 · 18 years
Last commercial register change
June 26, 2026
Employees
21 to 50
Legal form: Graded by liability and disclosure. The weight is kept small: a sole proprietorship is not a dubious company, it is just liable differently.
100.0
6%
  • Branch offices: Branch offices linked in the commercial register. Having none is normal and costs no points.70.03%
    • Full methodology

    Similar companies

    LT
    LifeMine Therapeutics (Switzerland) GmbH
    Basel
    NP
    Nxera Pharma CH Services GmbH
    Basel
    RG
    RXcel GmbH
    Basel
    VA
    VectivBio AG
    Basel
    SA
    Scailyte AG
    Basel
    AG
    AlphaMeld GmbH
    Basel
    PS
    PreClinical Safety (PCS) Consultants Ltd
    Basel
    IP
    Ironwood Pharmaceuticals GmbH
    Basel